Laura Mezquita

Grup de recerca

Genòmica translacional i teràpies dirigides en tumors sòlids Junior researcher (R2B)

lmezquita@clinic.cat 0000-0003-0936-7338

Publicacions destacades

Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

Autors:
Auclin, Edouard; Benitez-Montanez, Jose; Tagliamento, Marco; Parisi, Francesca; Gorria, Teresa;

(...)

Arasanz, Hugo; Rochand, Adrien; Besse, Benjamin; Routy, Bertrand; Mezquita, Laura.

Referència: Lung Cancer 2023.
Effects of spatial variation in dose delivery: what can we learn from radon-related lung cancer studies?

Autors:
Madas, Balazs G; Boei, Jan; Fenske, Nora; Hofmann, Werner; Mezquita, Laura;

Referència: Radiation And Environmental Biophysics 2022.
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Autors:
Mezquita, Laura; Preeshagul, Isabel; Auclin, Edouard; Saravia, Diana; Hendriks, Lizza;

(...)

Cassard, Lydie; Lopes, Gilberto; Chaput, Nathalie; Arbour, Kathryn; Besse, Benjamin.

Referència: European Journal Of Cancer 2021.
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer

Autors:
Ortiz-Cuaran, Sandra; Mezquita, Laura; Swalduz, Aurelie; Aldea, Mihalea; Mazieres, Julien;

(...)

Perol, Maurice; Besse, Benjamin; Blay, Jean-Yves; Saintigny, Pierre; Planchard, David.

Referència: Clinical Cancer Research 2020.
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

Autors:
Mezquita, Laura; Jove, Maria; Nadal, Ernest; Kfoury, Maria; Moran, Teresa;

(...)

Capella, Gabriel; Rouleau, Etienne; Lazaro, Conxi; Caron, Olivier; Besse, Benjamin.

Referència: Journal Of Thoracic Oncology 2020.
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer

Autors:
Mezquita, Laura; Swalduz, Aurelie; Jovelet, Cecile; Ortiz-Cuaran, Sandra; Howarth, Karen;

(...)

Massard, Christophe; Perol, Maurice; Friboulet, Luc; Besse, Benjamin; Saintigny, Pierre.

Referència: Jco Precision Oncology 2020.
Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients

Autors:
Mezquita, Laura; Benito, Amaro; Ruano-Ravina, Alberto; Zamora, Javier; Eugenia Olmedo, Maria;

(...)

Hernanz, Raul; Cabanero, Alberto; Auclin, Edouard; Carrato, Alfredo; Garrido, Pilar.

Referència: Clinical Lung Cancer 2019.
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Autors:
Mezquita, Laura; Auclin, Edouard; Ferrara, Roberto; Charrier, Melinda; Remon, Jordi;

(...)

Lahmar, Jihene; Adam, Julien; Chaput, Nathalie; Soria, Jean Charles; Besse, Benjamin.

Referència: Jama Oncology 2018.

Projectes destacats

Estudio EXPOS: Exposoma y medicina de precisión en pacientes con cáncer portadores de fusiones oncogénicas: entendiendo el papel de los carcinógenos y su implicación

Investigador/a principal: Laura Mezquita Pérez

Durada: 01/01/2024
Exposome & Precision Medicine in lung Cancer: understanding the role of carcinogens in clinical care

Investigador/a principal: Laura Mezquita Pérez

Durada: 01/01/2024
Impact of circulating neutrophils and tumor-associated neutrophils (TAN) in untreated advanced NSCLC treated with inmunotherapy and /or chemotherapy

Investigador/a principal: Laura Mezquita

Finançador: SEOM (Socieadad Española de Oncología Médica)

Durada: 31/10/2021

Laura Mezquita

Grup de recerca

Publicacions destacades

Projectes destacats

Estudio EXPOS: Exposoma y medicina de precisión en pacientes con cáncer portadores de fusiones oncogénicas: entendiendo el papel de los carcinógenos y su implicación

Exposome & Precision Medicine in lung Cancer: understanding the role of carcinogens in clinical care

Impact of circulating neutrophils and tumor-associated neutrophils (TAN) in untreated advanced NSCLC treated with inmunotherapy and /or chemotherapy

Subscriu-te a la Newsletter del Clínic